Review article · 2025 · Open access
A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
Molecular Neurodegeneration, 20(1), 88 · Published 6 August 2025 · DOI 10.1186/s13024-025-00872-7
In brief
“A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies” is a 2025 review article by Heike Hering and 6 co-authors, published in Molecular Neurodegeneration. OpenAlex counts 29 citations as of 15 November 2026, which puts it in the top 4% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Molecular Neurodegeneration.
- Citations
- 29
- Most cited in
- 2026 (25)
- Field-weighted impact
- 2.40
- References
- 223
- Authors
- 7
Abstract
After decades of disappointment, three disease-modifying therapies for Alzheimer's disease (AD) have been approved since 2021. Burgeoning clinical data on these amyloid β-protein (Aβ) targeting drugs validate the amyloid cascade hypothesis as a molecular roadmap for the development of yet more effective therapeutics and offer a template for drugging other AD-associated aggregation-prone proteins. While there remains much to be learned about the molecular pathology of AD, the current state of knowledge is sufficient to expedite the delivery of new drugs. Mindful of the urgent need of patients, we recommend prioritizing efforts in four directions: finishing the job on Aβ, accelerating and diversifying efforts on tau, and expanding discovery on apolipoprotein E and ⍺-synuclein. For each target, we explain the scientific premise, current efforts, and possible new approaches. In the short- and medium-term, we advocate focusing on the technical innovations required to better drug these already well validated targets. While the focus of this review is on expediating development of monotherapies, the subsequent approval of such agents will enable add-on or combination approaches best suited to individual patients.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025). A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies. Molecular Neurodegeneration, 20(1), 88. https://doi.org/10.1186/s13024-025-00872-7
MLA 9
Hering, Heike, et al. “A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies.” Molecular Neurodegeneration, vol. 20, no. 1, 2025, p. 88. https://doi.org/10.1186/s13024-025-00872-7.
Chicago
Hering, Heike, Thierry Bussière, Chia‐Chen Liu, Kelly E. Glajch, Andreas Weihofen, Jane L. Grogan, and Dominic M. Walsh. 2025. “A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies.” Molecular Neurodegeneration 20 (1): 88. https://doi.org/10.1186/s13024-025-00872-7.
Harvard
Hering, H. et al. (2025) ‘A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies’, Molecular Neurodegeneration, 20(1), p. 88. doi:10.1186/s13024-025-00872-7.
IEEE
H. Hering et al., “A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies,” Molecular Neurodegeneration, vol. 20, no. 1, p. 88, 2025, doi: 10.1186/s13024-025-00872-7.
BibTeX
@article{hering2025manifesto,
title = {{A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies}},
author = {Hering, Heike and Bussière, Thierry and Liu, Chia‐Chen and Glajch, Kelly E. and Weihofen, Andreas and Grogan, Jane L. and Walsh, Dominic M.},
journal = {Molecular Neurodegeneration},
year = {2025},
volume = {20},
number = {1},
pages = {88},
doi = {10.1186/s13024-025-00872-7},
url = {https://doi.org/10.1186/s13024-025-00872-7}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- drug discovery
- disease-modifying therapy
- amyloid-beta
- amyloid hypothesis
- tau protein
- apolipoprotein E
- alpha-synuclein
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025). A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies. Molecular Neurodegeneration, 20(1), 88. https://doi.org/10.1186/s13024-025-00872-7
How many times has this paper been cited?
29 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access: read the free full text at Molecular Neurodegeneration.
Who wrote this paper?
Heike Hering, Thierry Bussière, Chia‐Chen Liu, Kelly E. Glajch, Andreas Weihofen, Jane L. Grogan, Dominic M. Walsh.
What is the DOI of this paper?
10.1186/s13024-025-00872-7. The permanent link is https://doi.org/10.1186/s13024-025-00872-7.
Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.